Drug Trial Radar · NCT02864992
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
337
Actual
Start
Sep 13, 2016
Primary completion
May 16, 2022
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Aug 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Conditions
- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
- Lung Adenocarcinoma Stage IIIB/IV
Interventions
TepotinibDrug
Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)
- Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)
- Part 2: Cohort C: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC)Time frame: Time from first treatment up to data cutoff (approximately Month 66)
Locations
176 sites in 15 countries. Site status is shown where the registry gives one.
City of Hope Cancer Center
Duarte, California
California Cancer Associates for Research & Excellence, Inc.
Encinitas, California
St. Joseph Hospital
Orange, California
Torrance Health Association
Redondo Beach, California
St Joseph Heritage Healthcare
Santa Rosa, California
Rocky Mountain Cancer Centers, LLP
Denver, Colorado
Holy Cross Hospital Inc.
Fort Lauderdale, Florida
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida
University Cancer & Blood Center, LLC
Athens, Georgia
Winship Cancer Institute
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Ingalls Hospital
Harvey, Illinois
Community Regional Cancer Care
Indianapolis, Indiana
Center for Cancer and Blood Disorders
Bethesda, Maryland
For Recruiting Locations in the United States, please Contact U.S. Medical Information
Rockland, Massachusetts
St. Louis Cancer Care, LLP
Bridgeton, Missouri
Saint Louis University Cancer Center
St Louis, Missouri
Saint Louis University
St Louis, Missouri
Summit Medical Group, P.A.
Berkeley Heights, New Jersey
Summit Medical Group
Berkeley Heights, New Jersey
Regional Cancer Care Associates East Brunswick
East Brunswick, New Jersey
Somerset Hematology Oncology Associates - Somerville Location
East Brunswick, New Jersey
Hackensack University Medical Center PARTNER
Hackensack, New Jersey
Prospect Medical Offices, LLC
Midland Park, New Jersey
The Valley Hospital
Ridgewood, New Jersey
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York
Memorial Sloan Kettering Cancer Center, West Harrison Regional Outpatient Pavilion
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
UC Health Clinical Trials Office
Cincinnati, Ohio
University of Cincinnati - PARENT
Cincinnati, Ohio
Tennessee Oncology
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology, P.A. - Austin
Austin, Texas
Texas Oncology, PA
Beaumont, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Swedish Medical Center
Seattle, Washington
Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson
Wenatchee, Washington
Wenatchee Valley Medical Center Oncology
Wenatchee, Washington
LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie
Salzburg, Austria
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.